Comparative Activities of Novel Therapeutic Agents against Molecularly Characterized Clinical Carbapenem-Resistant <i>Enterobacterales</i> Isolates-Reference-Cited by-同舟云学术

Comparative Activities of Novel Therapeutic Agents against Molecularly Characterized Clinical Carbapenem-Resistant Enterobacterales Isolates

Published:2023-06-15 Issue:3 Volume:11 Page:
ISSN:2165-0497
Container-title:Microbiology Spectrum
language:en
Short-container-title:Microbiol Spectr

Author:

Teo Jocelyn Qi-Min¹^ORCID,Chang Hong Yi¹²,Tan Si Hui¹,Tang Cheng Yee³,Ong Rick Twee-Hee³,Ko Karrie Kwan Ki⁴^ORCID,Chung Shimin Jasmine⁵,Tan Thuan Tong⁵,Kwa Andrea Lay-Hoon¹⁶⁷^ORCID

Affiliation:

1. Department of Pharmacy, Singapore General Hospital, Singapore, Singapore

2. Department of Clinical Translational Research, Singapore General Hospital, Singapore, Singapore

3. Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore, Singapore

4. Department of Microbiology, Singapore General Hospital, Singapore, Singapore

5. Department of Infectious Diseases, Singapore General Hospital, Singapore, Singapore

6. Singhealth Duke-NUS Medicine Academic Clinical Programme, Singapore, Singapore

7. Emerging Infectious Diseases, Duke-National University of Singapore Medical School, Singapore, Singapore

Abstract

This study determined the susceptibilities of carbapenem-resistant Enterobacterales isolates to various novel antimicrobial agents (ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam, eravacycline, and plazomicin). Whole-genome sequencing was performed for all strains.

Funder

MOH | National Medical Research Council

National University of Singapore

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Cell Biology,Microbiology (medical),Genetics,General Immunology and Microbiology,Ecology,Physiology

Link

https://journals.asm.org/doi/pdf/10.1128/spectrum.01002-23

Reference27 articles.

1. Continuous Evolution: Perspective on the Epidemiology of Carbapenemase Resistance Among Enterobacterales and Other Gram-Negative Bacteria

2. U.S. Food and Drug Administration. 2019. Ceftazidime-avibactam. U.S. Food and Drug Administration website. http://www.accessdata.fda.gov/drugsatfda_docs/label/2019/206494s005 s006lbl.pdf. Accessed 27 October 2022.

3. U.S. Food and Drug Administration. 2019. Imipenem-cilastatin-relebactam. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212819s000lbl.pdf. Accessed 27 October 2022.

4. U.S. Food and Drug Administration. 2017. Meropenem-vaborbactam. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209776lbl.pdf. Accessed 27 October 2022.

5. U.S. Food and Drug Administration. 2018. Eravacycline. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211109lbl.pdf.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Expanding antibiotic, vaccine, and diagnostics development and access to tackle antimicrobial resistance;The Lancet;2024-06

2. Eravacycline: a comprehensive review of in vitro activity, clinical efficacy, and real-world applications;Expert Review of Anti-infective Therapy;2024-05-08

3. In Vitro Antimicrobial Activity of Five Newly Approved Antibiotics against Carbapenemase-Producing Enterobacteria—A Pilot Study in Bulgaria;Antibiotics;2024-01-15